Corrigendum: “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,” (Intest Res, (2023), 21(1), (137–147), (10.5217/ir.2021.00173))

Oh, Kyunghwan; Hong, Hee Seung; Ham, Nam Seok; Lee, Jungbok; Park, Sang Hyoung; Yang, Suk-Kyun; Yoon, Hyuk; Kim, You Sun; Choi, Chang Hwan; Ye, Byong Duk

doi:10.5217/ir.2021.00173.e

상세 보기

Corrigendum: “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,” (Intest Res, (2023), 21(1), (137–147), (10.5217/ir.2021.00173))

Oh, Kyunghwan;
Hong, Hee Seung;
Ham, Nam Seok;
Lee, Jungbok;
Park, Sang Hyoung;
... Choi, Chang Hwan;
외 4명

Citations

WEB OF SCIENCE

0

Citations

SCOPUS

0

초록

https://doi.org/10.5217/ir.2021.00173 Intest Res 2023;21(1):137-147 In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,”1 the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold. “Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/29 (59.2%) patients at week 8 and 26 (53.1%)/34 (69.4%) patients at week 20, respectively (Fig. 2)” © Copyright 2023. Korean Association for the Study of Intestinal Diseases

제목: Corrigendum: “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study,” (Intest Res, (2023), 21(1), (137–147), (10.5217/ir.2021.00173))

저자: Oh, Kyunghwan; Hong, Hee Seung; Ham, Nam Seok; Lee, Jungbok; Park, Sang Hyoung; Yang, Suk-Kyun; Yoon, Hyuk; Kim, You Sun; Choi, Chang Hwan; Ye, Byong Duk

DOI: 10.5217/ir.2021.00173.e

발행일: 2023-04

유형: Correction

저널명: Intestinal research

권: 21

호: 2

페이지: 273 ~ 273